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Despite the objections to transplant tourism raised by the
transplant community, many patients continue travel to
other countries to receive commercial transplants. To
evaluate some long-term complications, we reviewed
medical records of 215 Taiwanese patients (touring group)
who received commercial cadaveric renal transplants in
China and compared them with those of 321 transplant
recipients receiving domestic cadaveric renal transplants
(domestic group) over the same 20-year period. Ten years
after transplant, the graft and patient survival rates of the
touring group were 55 and 81.5%, respectively, compared
with 60 and 89.3%, respectively, of the domestic group.
The difference between the two groups was not statistically
significant. The 10-year cumulative cancer incidence of the
touring group (21.5%) was significantly higher than that of
the domestic group (6.8%). Univariate and multivariate
stepwise regression analyses (excluding time on
immunosuppression, an uncontrollable factor) indicated that
transplant tourism was associated with significantly higher
cancer incidence. Older age at transplantation was associated
with a significantly increased cancer risk; however, the risk of
de novo malignancy significantly decreased with longer graft
survival. Thus, renal transplant tourism may be associated
with a higher risk of post-transplant malignancy, especially
in patients of older age at transplantation.
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Shortage of donor kidneys is a serious problem for patients
awaiting renal transplantation. Although the transplant
community objects to transplant tourism, many patients,
including Taiwanese, visit China to receive commercial renal
transplants from executed prisoners.1,2 The graft and patient
survival rates of renal transplant tourists were previously
reported to be comparable with those of legitimate recipients
in Taiwan, but long-term complications such as cancer
incidence was not addressed.3,4
Post-transplant malignancy is becoming one of the most
important causes of patient morbidity and mortality after
renal transplantation.5–7 The patterns of de novo malignancy
after renal transplantation differed by population and
immunosuppressive agents. A high incidence of skin cancer
after renal transplantation was reported in Australia and New
Zealand, and the average time from transplantation to cancer
was 9.4 years.6 Besides, T-cell-depletive induction therapy
was found to be associated with post-transplant cancer,
mostly skin cancer and cancer of the genitourinary tract, at a
mean time of 27 months.8 However, transplant tourism is an
exceptionally secret transplant activity with concealed donor
data and obscure peri-operative course and management.
The vague transplant information could make the follow-up
care of transplant tourists a difficult task and lead to more
complications.4
The medical records of renal transplant patients who
received commercial cadaveric renal transplants anywhere in
China (touring group) were collected and compared with
those of patients who received cadaveric transplants in
our department (domestic group) during the past 20 years.
Our transplant team provided post-transplant care to all
patients in our hospital without discrimination. Cancer
incidences and the associated risk factors were studied using
univariate and multivariate regression analyses to identify the
risk factors associated with post-transplant malignancy.
RESULTS
Baseline characteristics
Baseline characteristics for the touring and domestic groups
are shown in Table 1. On average, patients in the touring
group were older at the time of transplantation (45.8±11.9
years) compared with those in the domestic group
(39.7±11.0 years) (Po0.0001). The average donor age of
the domestic group was 34.9±13.6 years, and human
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leukocyte antigen mismatches were 3.2±1.3. However, donor
age and human leukocyte antigen mismatches were not
available for any patients in the touring group because donor
identity was always obscured. Patients in the touring and
domestic groups were followed up, on average, for 76.2±48.1
months and 81.5±53.4 months, respectively.
Immunosuppressive therapy and outcome
None of the patients in the domestic group received antibody
induction therapy, except four patients (1.2%), who were
once enrolled in a clinical trial using anti-CD25 antibody
induction therapy. Of the 215 recipients in the touring group,
23 (10.7%) were traced to have received a depleting antibody
induction therapy, such as thymoglobulin, anti-lymphocyte
globulin, or OKT3, and 16 (7.4%) received anti-CD25
antibody induction. Most of the cases were not given medical
referral sheets for aftercare. The differences in the percentages
of antibody induction therapy reached statistical significance.
As the percentage of antibody induction may be higher in the
touring group, the P-values may be more significant (Table 2).
In the domestic group, 72 patients (22.4%) received
tacrolimus-based immunosuppressive de novo therapy and
245 (76.3%) received cyclosporine-based therapy. A total of
89 patients (41.4%) of the touring group received tacrolimus
de novo therapy, and 126 (58.6%) received cyclosporine; the
touring group included more patients on tacrolimus than did
the domestic group (Po0.0001). In addition, none of the
touring group patients received sirolimus de novo therapy,
but 63 of the domestic group (19.6%) patients received
de novo sirolimus therapy (Po0.0001), with or without a
low-dose calcineurin inhibitor. The overall acute rejection
rate of the domestic group was 29.6%, but the history of
acute rejection in China could not be traced for the touring
group. The graft and patient survival rates of the touring
group were 55.0 and 81.5% at 10 years, respectively,
and those of the domestic group were 60.0 and 89.3%,
respectively. The results of the touring group seemed inferior
to those of the domestic group, but the difference between
the two groups did not reach statistical significance.
De novo malignancy
The incidence of first malignancy was higher in the touring
group than in the domestic group (Po0.0001). The 5-year
cancer incidence rate was 15.5% for the touring group and
2.8% for the domestic group. The 10-year cancer incidence
rate was 21.5% for the touring group and 6.8% for the
domestic group. The 10-year cancer-free patient survival was
significantly (P¼ 0.0117) reduced in the touring group
(76.5%) than in the domestic group (85.4%). The patholo-
gical diagnosis of post-transplant malignancy is summarized
in Table 3a. Urothelial carcinoma was the most common
post-transplant malignancy, accounting for 46.9% (15/32)
and 26.7% (4/15) of the pathological diagnosis in the touring
and domestic groups, respectively. The percentages of
urothelial carcinoma and hepatocellular carcinoma in the
two groups were not significantly different. Most of the
patients with urothelial carcinoma had multicentric tumors;
11 of the touring group and 2 of the domestic group had
urothelial carcinoma involving more than 1 site in the native
urinary tract. No graft urothelial carcinoma was found.
Locations of the urothelial carcinoma are summarized in
Table 3b.
Hepatocellular carcinoma, which could be associated with
high hepatitis B or hepatitis C infection rates in Taiwan, was
the second most common de novo cancer in the touring
group (9/32, 28.1%) and in the domestic group (3/15,
20.0%). In all, 5 of the 12 patients with hepatocellular
carcinoma were positive for hepatitis B surface antigen, and
another 5 were positive for anti-hepatitis C antibody. Two
patients were negative for hepatitis B or C. All the
hepatocellular carcinomas happened in the liver and beyond
3 years after transplantation, except in four patients of the
Table 1 | Demographics and viral hepatitis profiles of the
touring group receiving commercial renal transplants in
China and of the domestic group having legitimate
transplants in Taiwan between 1987 and 2006
Characteristics
Touring
group
(n=215)
Domestic
group
(n=321) P-valuea
Age at transplantation
(years)
45.8±11.9 39.7±11.0 o0.0001
Gender (male:female) 102:113 158:163 NS
Donor age (years) NA 34.9±13.6 —
HLA mismatches NA 3.2±1.3 —
HBsAg () and anti-HCV () 145 (67.4%) 223 (69.5%) NS
HBsAg (+) 40 (18.6%) 46 (14.3%) NS
Anti-HCV (+) 36 (16.7%) 74 (23.1%) NS
Follow-up (months) (range) 76.2±48.1
(3–217)
81.5±53.4
(1–250)
NS
Abbreviations: Anti-HCV, anti-hepatitis C antibody; HBsAg, hepatitis B surface
antigen; HLA, human leukocyte antigen; NA, not available; NS, not significant.
aTwo-tailed Fisher’s exact test was used for categorical variables; two-tailed
unpaired t-test was used for continuous variables.
Table 2 | Antibody induction, immunosuppressive therapy,
and outcome of the touring and domestic groups
Treatment and outcome
Touring
group
(n=215)
Domestic
group
(n=321) P-valuea
Depleting antibody induction X23 (10.7%)b 0 o0.0001b
Anti-CD25 antibody induction X16 (7.4%)b 4 (1.2%) p0.0002b
Tacrolimus:cyclosporine 89:126 72:245 o0.0001
Initial sirolimus 0 63 (19.6%) o0.0001
Acute rejection NA 95 (29.6%) —
5/10-year graft survival 75.5%/55.0% 78.9%/60.0% NS
5/10-year patient survival 88.1%/81.5% 94.9%/89.3% 0.0802
5/10-year cancer incidence 15.5%/21.5% 2.8%/6.8% o0.0001
5/10-year cancer-free patient
survival
81.3%/76.5% 92.5%/85.4% 0.0117
Abbreviations: NA, not available; NS, not significant.
aTwo-tailed Fisher’s exact test was used for categorical variables; log-rank test was
used for survival analysis.
bAs the percentage of antibody induction may be higher in the touring group, the P-
values may be more significant.
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touring group, who had hepatocellular carcinoma within
2 years. There were three cases and one case of post-
transplant lymphoproliferative disease in the touring and
domestic groups, respectively. Skin cancer was relatively rare
in Taiwan; each group reported only one patient diagnosed
with non-melanoma skin cancer. Nearly half of the de novo
malignancies were diagnosed during the early first 3 years
after transplantation. Two patients of the touring group had
urothelial carcinoma of the bladder within 6 months,
suggesting that some patients especially those in the touring
group might have actually had cancer before kidney
transplantation. The time periods for cancer occurrence are
summarized in Table 3c.
Univariate and multivariate analyses
A univariate analysis of the prognostic factors for de novo
malignancy among all cases showed that, in addition to
transplant tourism (Po0.0001), age at transplantation
(P¼ 0.0001) and time on immunosuppressive therapy
(Po0.0001) were significant prognostic factors (Table 4).
Older age (in years) at transplantation was associated with a
higher risk (ratio¼ 1.0550) of cancer after transplantation.
However, the longer the time (in months) the patients
were on immunosuppressive therapy, the lower the risk
(ratio¼ 0.9741) that they were to develop de novo malig-
nancy. Results of the multivariate regression analysis are
shown in Table 5a. The initial multivariate regression model
for de novo malignancy indicated that the three factors in
the univariate analysis were significant at the 0.05 level.
Excluding time on immunosuppression, which is not a
controllable factor, stepwise regression procedures were
applied, and a regression model including transplant tourism
and age at transplantation was selected. In this model,
transplant tourism presented a hazard ratio of 2.7793, and
age at transplantation presented a ratio of 1.0408 per year
(Table 5b).
DISCUSSION
It is an interesting phenomenon that transplant tourism
was an independent risk factor for post-transplant malig-
nancy in this study. It may be due to the relatively low
incidence (6.8% at 10 years) of cancer in the domestic group
or, on the contrary, a higher incidence (21.5% at 10 years) in
the touring group. In fact, the 10-year cancer incidence rate
of domestic group patients was similar to that of heart
(8.1%) transplant patients in our hospital. Cancer incidence
(8.3–8.8%) reported by other renal transplant centers
in Taiwan were also comparable with our results.9–12 It is
suggested that transplant tourism was associated with a
higher risk of de novo malignancy after renal transplantation.
Transplant tourism may be a surrogate factor of many
associated factors associated with post-transplant malig-
nancy. In this study, patients seeking commercial renal
transplants in China were, on average, 6 years older than
recipients who received domestic renal transplants. The
possible reasons for the older age of transplant tourists might
be at least twofold. Transplant tourists are older and more
socially and economically stable to afford the expense of the
transplant. In addition, older patients might think that
they do not stand a chance to receive deceased renal
transplants in Taiwan, because children are given priority
in the scoring system (see http://www.torsc.org.tw/assize/
assizeWaitKidney.jsp). Although age and transplant tourism
Table 3 | (a) Pathologya, (b) locations of urothelial carcinoma
and (c) time periods of post-transplant de novomalignancy in
the touring and domestic groups
Touring
group
(n=32)
Domestic
group
(n=15) P-valueb
(a)
Urothelial carcinoma 15/32 (46.9%) 4/15 (26.7%) NS
Hepatocellular carcinoma 9/32 (28.1%) 3/15 (20.0%) NS
Gastrointestinal carcinoma 3/32 (9.4%) 2/15 (13.3%) NS
(colon/pancreas/diffuse) (1/1/1) (2/0/0)
PTLD 3/32 (9.3%) 1/15 (6.7%) NS
(stomach/colon/bone
marrow/graft) (1/1/1/0) (0/0/0/1)
Gynecological cancer 0 2/15 (13.3%) NS
(cervix/corpus) (1/1)
Breast cancer 1/32 (3.1%) 2/15 (13.3%) NS
Skin cancer (non-melanotic) 1/32 (3.1%) 1/15 (6.7%) NS
Touring
group
(n=15)
Domestic
group
(n=4)
(b)
Solitary 4 2
(kidney/ureter/bladder) (2/1/1) (0/1/1)
Multicentric 11 2
(Kidney/ ureter/ bladder)c
O U O (3)
U O U (1)
U U U (3)
U B O (1)
U B U (2)
B O U (1)
B U O (1)
B B U (1)
Touring
group (n=32)
Domestic
group (n=15)
(c)
Within 6 months 2/32 (6.3%) 0
From 6 months to 3 years 14/32 (43.8%) 7/15 (46.7%)
From 3 to 6 years 13/32 (40.6%) 1/15 (6.7%)
From 6 to 10 years 1/32 (3.1%) 4/15 (26.7%)
Beyond 10 years 2/32 (6.3%) 3/15 (20.0%)
Abbreviations: NS, not significant; PTLD, post-transplant lymphoproliferative disorder.
aIn case of multiple cancers, only the first cancer was counted.
bValues represent two-tailed Fisher’s exact test.
cFor multicentric tumors, B stands for bilateral, U for unilateral or urinary bladder, and O
for no tumor.
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were independent factors for de novo malignancy after
renal transplantation, some factors other than age must be
associated with transplant tourism to increase the incidence
of post-transplant cancers.13
Immunosuppressive therapy may be one of the most
important factors associated with post-transplant cancers in
renal transplant patients.14 In a previous study, sirolimus
reduced the incidence of post-transplant cancers.15 However,
in this study, sirolimus was not an independent factor for
cancer incidence in the univariate analysis. Interestingly, the
timing of post-transplant malignancy was much earlier,
especially in the touring group, than that reported in the
literature.16 Two patients of the touring group had urothelial
carcinoma of the bladder within 6 months, and nearly half of
the post-transplant cancers of our patients were diagnosed
within 3 years. Little wonder that time on immunosuppres-
sive therapy was negatively related to cancer occurrence in
this study. It is suggested that post-transplant cancer mostly
occurred before or early after transplantation in our patients,
possibly associated with antibody induction therapy or
herbal medicine used before transplantation.8,12
Reviewing the immunosuppressive regimens used in
transplant tourists, we found that significantly more
transplant tourists received depleting antibody induction,
which has been reported to cause more cancers in transplant
patients.17,18 In addition, the percentage of depleting anti-
body induction therapy among the touring group may be
much higher, as the medication history of transplant tourists
was sometimes difficult to trace. It was difficult to obtain any
information from patients, and no referrals were available in
most patients of the touring group. Although depleting
antibody induction was not shown to be a significant factor
associated with post-transplant malignancy, the effect of
depleting antibody induction on post-transplant malignancy
was underestimated.
The pattern of post-transplant malignancy in our patients
was different from that in the Australian or other Western
populations. Urothelial carcinoma and hepatocellular carci-
noma, which were not common in Western countries,
however, prevailed in this study and in other studies from
Taiwan.12,19 Considering the high percentage of urothelial
carcinoma, we believed that Chinese herbal medications
containing aristolochic acid contributed to the high in-
cidence of urothelial carcinoma in our patients. Aristolochic
acid can facilitate diuresis and delay the urgency for dialysis
in uremic patients. It was common practice to use Chinese
herbal medications containing aristolochic acid to treat
patients with renal failure and who could not accept dialysis.
Herbal medications containing aristolochic acid were not
prohibited until recently when aristolochic acid was proved
nephrotoxic and carcinogenic.20 However, other potential
risk factors of urothelial carcinoma, including analgesic
use and chronic arsenic exposure from underground water,
might still have roles in our patients.21,22 Compound
analgesics were previously placed over the counter and
readily available in Taiwan. Some of our patients did use
underground water, although the concentration of arsenic
had not been measured. The causes of urothelial carcinoma
in Taiwanese renal transplant patients should be multi-
factorial; it was difficult to establish the cause–effect and
dose–response relationship for those contributing factors that
actually conspired toward renal failure and transplantation a
long time before cancer occurrence.
Hepatocellular carcinoma was the second most common
cancer in our patients and should be associated with the high
incidence of viral hepatitis in Taiwan.23 Hepatitis B carriers
Table 5 |Multivariate Cox regression analysis of the factors with statistical significance in the univariate analysis
Cox regression
Regression
coefficient s.e. Risk ratio P-value
(a) Initial multivariate regression analysis
Transplant tourism 1.0311 0.3272 2.8043 0.0016
Age at transplantation 0.0307 0.0138 1.0312 0.0259
Time on immunosuppressive therapy 0.0254 0.0059 0.9750 o0.0001
(b) The final regression model after stepwise regression procedures
Transplant tourism 1.0222 0.3269 2.7793 0.0018
Age at transplantation 0.0400 0.0139 1.0408 0.0041
Table 4 | Univariate analysis of prognostic factors for cancer incidence
Log-rank test Category
No. of
patients
Five-year cumulative
cancer incidence P-value
Transplant tourism Yes
No
215
321
15.5%
2.8%
o0.0001
Cox’s regression Regression coefficient s.e. Risk ratio P-value
Age at transplantation 0.0535 0.0137 1.0550 0.0001
Time on immunosuppressive therapy 0.0262 0.0057 0.9741 o0.0001
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accounted for 10–17% of the general adult population
born before the universal hepatitis B vaccination program
in Taiwan in 1984, and the prevalence of anti-hepatitis
C antibody was approximately 8.5–14.5%, with a growing
tendency in the advanced stages of chronic kidney dis-
ease.24,25 Viral hepatitis status, either hepatitis B or C, was
not a significant factor for post-transplant malignancy in this
study because hepatocellular carcinoma was not the most
prevalent cancer in our patients. In addition, the observation
period in this study might be inadequate for hepatocellular
carcinoma to develop in patients with chronic viral hepatitis.
Skin cancer (one patient in each group) and post-transplant
lymphoproliferative disorder (three patients in each group)
were not common in our patients, which would account for
the relative low incidence of cancers (6.8% at 10 years) in our
domestic group, as compared with those in the literature.26
Renal transplant tourists comprised a distinct group of
patients with unique disease patterns, treatment, and
outcomes. High incidences of unconventional infections
and surgical complications were reported.4 Difficulty in
follow-up transplant care was raised when information
regarding the donor, transplant operation, and early post-
transplant recovery was not revealed in transplant tourism.
It would be difficult to improve on post-operative manage-
ment, because there was no feedback from follow-up
physicians to the surgical teams regarding surgical and
medical complications. Owing to the lack in mutual
communication between the surgical and follow-up trans-
plant teams, transplant tourism can hardly develop into a
modern transplant care system, which aims to improve
patients’ quality of life and not just graft or patient
survival.27,28 The graft and patient survival rates of transplant
tourists were actually inferior to those of domestic patients in
this study; more patient numbers and longer follow-up time
would make the differences reach statistical significance. In
addition, the high incidences of post-transplant cancers
associated with transplant tourism deserve a careful
consideration. The early occurrence of cancers in the touring
group (two cases of urothelial carcinoma within 6 months
and four cases of hepatocellular carcinoma within 2 years)
implied that some of the transplant tourists might
have cancer before transplantation. The importance of pre-
transplant evaluations cannot be overemphasized.
In conclusion, renal transplant tourism, as compared with
domestic transplantation, was found to present an increased
risk of post-transplant malignancy, which might be related
to older age at transplantation, more depleting antibody
induction therapy, and omitted pre-transplant cancer
screening.
MATERIALS AND METHODS
Study group
A retrospective study was conducted to assess the outcome of renal
transplant tourism. The medical records of 215 renal transplant
tourists who received cadaveric renal transplantation between
January 1987 and December 2006 in China and post-transplant
care in our hospital were reviewed (touring group). Patients with
second transplants or pre-transplant cancers were not included. The
outcomes of the touring group were compared with those of the 321
transplant recipients receiving cadaveric renal transplants in our
department (domestic group) during the same period.
Transplant evaluations and follow-up
For the domestic group, patients underwent complete pre-
transplant evaluations before waiting on the list, including history
taking, physical examination, complete blood counts, biochemistry,
blood sugar, urine cytology, urinalysis, coagulation profiles, chest
and abdominal films, abdominal sonography, human lymphocyte
antigens, blood type, preformed antibody, electrocardiograms, and
virology profiles. Chinese herbal medication was expressly forbidden
during the waiting and post-transplant periods. However, for the
touring group, pre-transplant evaluations were not instituted
because tourist transplant activities could not be fully organized.
Herbal medication was also prohibited during the post-transplant
follow-up of the touring group, but the history of herbal medication
before transplantation could not be discovered. Recipients with graft
survivalo1 month were not included in the domestic group, as the
touring group could not possibly include patients with peri-
operative mortality or graft failure within 1 month. Multiple solid
organ transplants and renal transplantation with ABO incompat-
ibility or positive lymphocytotoxicity were excluded.
Immunosuppressive regimens
For the touring group, the initial immunosuppressive regimens
used in China were not changed unless patients showed signs
of intolerance. The dosage of calcineurin inhibitors, either
cyclosporine or tacrolimus, was adjusted to the target trough levels
of 200–400 ng/ml for cyclosporine or to those of 8–16 ng/ml for
tacrolimus. The target blood levels at 12 months were 100–200 ng/ml
for cyclosporine and 5–8 ng/ml for tacrolimus. Mycophenolate
mofetil or mycophenolate sodium was prescribed at initial doses of
1–2 g/day or 720–1440 mg/day, respectively. Azathioprine was used in
some early cases at doses between 50 and 100 mg/day. White blood
cell counts were controlled between 4000 and 6000/mm3, unless
intolerance developed or the maximum dose was reached. The
history of antibody induction therapy was traced when patients
presented themselves for aftercare in our hospital. Prednisolone dose
was 2.5–5 mg/day at 12 months and thereafter. Prednisolone could
be tapered down or even discontinued if significant side effects
occurred.
For the domestic group, the immunosuppressive regimens were
basically the same as those for the touring group: a calcineurin
inhibitor combined with steroids and an anti-proliferative agent,
mycophenolate mofetil, mycophenolate sodium, or azathioprine.
None of the domestic group patients received antibody induction
therapy except for four patients who joined a clinical trial and
received anti-CD25 (basiliximab) induction therapy. A total of 63
patients of the domestic group received sirolimus de novo therapy in
combination with reduced doses of oral cyclosporine or tacrolimus;
the initial target trough levels were 100–200 ng/ml for cyclosporine
and 4–8 ng/ml for tacrolimus.29 Sirolimus was administered at a
loading dose of 6 mg within 48 h after graft reperfusion, followed by
2 mg/day as maintenance. The trough levels of sirolimus were
measured using the Abbott IMx sirolimus assay (Abbott, Chicago,
IL) and adjusted if side effects occurred. The target blood levels at
12 months were 50–150 ng/ml for cyclosporine, 3–6 ng/ml for
tacrolimus, and 4–8 ng/ml for sirolimus.
912 Kidney International (2011) 79, 908–913
or ig ina l a r t i c l e M-K Tsai et al.: Malignancy in renal transplant tourism
Statistical analysis
Univariate and Cox’s multivariate analyses were performed using
NCSS 2008 for Windows software (Kaysville, UT). Values reported
are arithmetic mean±s.d. Unpaired two-tailed t-tests and Fischer’s
exact tests were used for normally distributed continuous variables
and categorical variables, respectively. The P¼ 0.05 level was
adopted as the level of significance. Graft and patient survival,
cancer incidence, and cancer-free patient survival rates were
estimated using the Kaplan–Meier method. In patients with multiple
cancer types, only the first cancer was recorded. Univariate analysis
with the log-rank test was used to examine the prognostic
significance of transplant tourism, recipient gender, donor type,
hepatitis B surface antigen status, anti-hepatitis C antibody status,
sirolimus therapy, calcineurin inhibitor (cyclosporine or tacrolimus)
therapy, and depleting or non-depleting antibody induction
on cancer incidence. The prognostic significance of recipient age
and time on immunosuppressive therapy for graft survival was
determined by Cox regression. Multivariate regression analysis was
then applied to factors with statistical significance in the univariate
analysis to further determine the independent effect of each factor.
Stepwise regression procedures were performed to select a model
of controllable factors with a maximal corresponding likelihood
ratio statistic.
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